0
0.5
1
1.5
2+
Mortality
10%
Improvement
Relative Risk
c19 hcq.org
Turrini et al. HCQ for COVID-19 LATE TREATMENT
Is late treatment with HCQ beneficial for COVID-19?
Retrospective 205 patients in Italy
No significant difference in mortality
Turrini et al., Vaccines, 10.3390/vaccines9060640
Favors HCQ
Favors control
Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy
Turrini et al., Vaccines, 10.3390/vaccines9060640
Turrini et al. , Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como,.. , Vaccines, 10.3390/vaccines9060640
Retrospective 205 patients in Italy, 160 treated with HCQ, showing lower mortality with treatment in multivariate analysis, but not reaching statistical significance.
risk of death, 9.8% lower , RR 0.90, p = 0.15 , treatment 103 of 160 (64.4%), control 33 of 45 (73.3%), NNT 11, adjusted per study, odds ratio converted to relative risk, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Turrini et al., 11 Jun 2021, retrospective, Italy, peer-reviewed, 16 authors.
Abstract: Article
Clinical Course and Risk Factors for In-Hospital Mortality of
205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy
Region, Italy
Mauro Turrini 1, * , Angelo Gardellini 1 , Livia Beretta 2 , Lucia Buzzi 3 , Stefano Ferrario 4 , Sabrina Vasile 5 ,
Raffaella Clerici 6 , Andrea Colzani 4 , Luigi Liparulo 7 , Giovanni Scognamiglio 8 , Gianni Imperiali 9 ,
Giovanni Corrado 10 , Antonello Strada 11 , Marco Galletti 12 , Nunzio Castiglione 13 and Claudio Zanon 13
1
2
3
4
5
6
7
8
9
Citation: Turrini, M.; Gardellini, A.;
Beretta, L.; Buzzi, L.; Ferrario, S.;
10
Vasile, S.; Clerici, R.; Colzani, A.;
11
Liparulo, L.; Scognamiglio, G.; et al.
Clinical Course and Risk Factors for
In-Hospital Mortality of 205 Patients
with SARS-CoV-2 Pneumonia in
Como, Lombardy Region, Italy.
Vaccines 2021, 9, 640. https://
doi.org/10.3390/vaccines9060640
Academic Editors: Ralph A. Tripp,
Steven B. Bradfute and Scott Anthony
Received: 1 May 2021
Accepted: 8 June 2021
Published: 11 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
12
13
*
Department of Medicine, Division of Hematology, Valduce Hospital, 22100 Como, Italy;
agardellini@valduce.it
Risk Management, Valduce Hospital, 22100 Como, Italy; lberetta@valduce.it
Quality Management System, Valduce Hospital, 22100 Como, Italy; lbuzzi@valduce.it
Department of Medicine, Division of Pneumology, Valduce Hospital, 22100 Como, Italy;
sferrario@valduce.it (S.F.); acolzani@valduce.it (A.C.)
Department of Mother and Child, Division of Paediatric and Neonatology, Infectious Diseases Consultant,
Valduce Hospital, 22100 Como, Italy; svasile@valduce.it
Department of Medicine, Division of Neurology, Valduce Hospital, 22100 Como, Italy; rclerici@valduce.it
Department of Medicine, Division of Internal Medicine, Valduce Hospital, 22100 Como, Italy;
lliparulo@valduce.it
Department of Medicine, Division of Oncology, Valduce Hospital, 22100 Como, Italy; giosco@valduce.it
Department of Medicine, Division of Gastroenterology, Valduce Hospital, 22100 Como, Italy;
g.imperiali@libero.it
Department of Medicine, Division of Cardiology, Valduce Hospital, 22100 Como, Italy; gcorrado@valduce.it
Department of Emergency Medicine, Valduce Hospital, 22100 Como, Italy; astrada@valduce.it
Department of Intensive Care Medicine, Valduce Hospital, 22100 Como, Italy; mgalletti@valduce.it
Hospital Health Management, Valduce Hospital, 22100 Como, Italy; ncastiglione@valduce.it (N.C.);
zanonclaudio762@gmail.com (C.Z.)
Correspondence: mturrini@valduce.it; Tel.: +39-031324419
Abstract: The aim of this study is to explore risk factors for in-hospital mortality and describe the
effectiveness of different treatment strategies of 205 laboratory-confirmed cases infected with SARSCoV-2 during the Lombardy outbreak. All patients received the best supportive care and specific
interventions that included the main drugs being tested for repurposing to treat COVID-19, such
as hydroxychloroquine, anticoagulation and antiviral drugs, steroids, and interleukin-6 pathway
inhibitors. Clinical, laboratory, and treatment characteristics were analyzed with univariate and
multivariate logistic regression methods to explore their impact on..
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit